#AAO22: Iver­ic Bio, un­de­terred by loom­ing PDU­FA for com­peti­tor, touts sub­group da­ta on GA drug

CHICA­GO — While its com­peti­tor is on the cusp of like­ly se­cur­ing the first FDA nod, Iver­ic Bio is trudg­ing ahead with its po­ten­tial treat­ment for ge­o­graph­ic at­ro­phy, an ad­vanced form of AMD, and has new da­ta to sup­port its up­com­ing NDA fil­ing.

The biotech said its drug was more fa­vor­able than sham across all sub­groups in the sec­ond Phase III study of the in­ves­ti­ga­tion­al com­ple­ment C5 pro­tein in­hibitor, per­form­ing sim­i­lar­ly to a pre­vi­ous, small­er late-stage tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER